Long-term effects of an inotropic phosphodiesterase inhibitor (ICI 153,110) on the rat salivary gland, harderian gland, and intestinal mucosa.
The inotropic vasodilator, ICI 153,110, a phosphodiesterase inhibitor intended for the treatment of congestive heart failure, was administered to Alderley Park Wistar-derived rats for periods of up to 182 days. Treatment produced hypertrophy of salivary glands, hyperplasia of intestinal mucosa, and dacryoadenitis of the harderian gland. As the functions of these glandular tissues can be modified by factors which alter cyclic nucleotide metabolism, it is postulated that the glandular alterations produced by ICI 153,110 occurred as a result of phosphodiesterase inhibition.
Westwood
F R
FR
Safety of Medicines Department, ICI Pharmaceuticals, United Kingdom.
Iswaran
T J
TJ
Greaves
P
P
D000818:Animals; D004064:Digestive System / Q000187:drug effects; D004068:Digestive System Physiological Phenomena; D004095:Dihydropyridines / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006243:Harderian Gland / Q000187:drug effects* / Q000473:pathology; D006965:Hyperplasia; D006984:Hypertrophy; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D011724:Pyridazines / Q000009:adverse effects*; D051381:Rats; D011919:Rats, Inbred Strains; D012469:Salivary Glands / Q000187:drug effects* / Q000473:pathology; D013997:Time Factors; D014665:Vasodilator Agents / Q000009:adverse effects*
D004095:Dihydropyridines; D010726:Phosphodiesterase Inhibitors; D011724:Pyridazines; D014665:Vasodilator Agents; C064747:ICI 153110